Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by bilosellhion Apr 30, 2003 9:50pm
401 Views
Post# 6057437

more questions than answers

more questions than answerswhy was the stock not halted by the exchange and the company not asked to comment on the trading activity? if the answer is that it was due to a US stock newsletter recommendation, i'm not sure that is good news - especially if the hype contained in the excerpts posted here are representative of the report. suggesting onc is the next microsoft or macdonalds at this stage may certainly add to the hype and excitement, and perhaps price, but it is anything but a realistic comparison to make at this point or a solid basis for a sustained increase in price. i don't consider stock newsletter readers as paritularly informed buying - and i also think that a pp right around the corner is a distinct possibility - there has been no news on the glio delay now entering its 5th month and there have only been 6 prostate patients treated in the 1 year that trial has been going on. with limited results like that, it is unlikely that they will see serious partner money anytime soon, and they are still burning cash at $500K/month. they are likely running well below Brad's 12 month cash cushion, and will run dangerously low over the next few months, if the cash isn't replenished somehow, especially considering they want to start a third systemic trial. depending on the volume, i think tomorrow may present a good selling opportunity.
Bullboard Posts